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journal homepage : www.e lsev ie r . com/ loca te / rmedLETTER TO THE EDITORReply to: Kelly et al. Alpha-1-antitrypsin deficiencyI recently read the Alpha-1-antitrypsin review in press by
Kelly and colleagues (Kelly E et al, Alpha-1-antitrypsin defi-
ciency. Respir Med 2010; 104:763e772). Interest in this
genetic predisposition to COPD and especially the processes
that lead to emphysema has received a welcomed increase.
Although the review is comprehensive there are some
aspects I feel deserve further comment. Firstly, the rela-
tionship to Bronchiectasis. With the advent of CT scanning
the identification of pathologically dilated bronchi has been
easy to detect. The incidence of these typical changes
consistent with Bronchiectasis has been described in about
30% of patients with usual COPD1 as well as in AATD.
Whether this is synonymous with the condition recognised
previously by clinicians remain largely unknown. However,
in A1ATD a subsequent careful description by Parr and
colleagues demonstrated that abnormally dilated bronchi
were present in most patients with A1ATD2 and co-located
with the emphysema suggesting that similar proteolytic
events were responsible although generally an observation
rather than a clinical problem. This supports the concept
that Bronchiectasis is not a more specific problem in AATD.
Secondly, the role of genetic modifiers is becoming
clearer and several studies have now suggested this
concept.3 However, the problem with genetic studies is the
confirmation in a second data set. The rarity of this
condition means that adequate DNA databases are only
likely to exist on different continents or at least countries.
Background racial origins and subsequent mixes may
therefore also influence any replication results. Neverthe-
less such collaborative studies are underway.
Thirdly, the costs of screening vary. Levels are least
expensive and identify low levels, which is the main risk
factor, phenotyping is informative but may miss null geno-
types. Genotyping is the most accurate but also most
expensive. In the article genotyping is recommended but no
evidence to support its role in “providing more information
about the likelihood of developing clinical consequences
such as liver and lung disease”. It would be helpful to the
uninformed reader to understand this statement.
Fourthly, treatment is mentioned. Although the weight of
circumstantial evidence suggests augmentation is beneficial itDOI of original article: 10.1016/j.rmed.2010.01.016.
0954-6111/$ - see front matter ª 2010 Published by Elsevier Ltd.
doi:10.1016/j.rmed.2010.04.028remains impractical to perform a controlled clinical trial
powered to prove/disprove efficacy using previously accepted
outcomes such as FEV1. CT densitometry has become the gold
standard for monitoring emphysema progression. It is more
sensitivethanphysiology4 and is thebestpredictorofmortality
in this disease.5 The authors describe one previous controlled
trial showing benefit of augmentation therapy for this
parameter.6 The finding itself was not significant (pZ 0.07).
However, a subsequent trial4 also demonstrated a similar
findingwhere themost sensitivemethodofanalysing the scans
gave a p value of 0.049. Indeed subsequent regional analysis
confirmed that this effect was clearest (pZ 0.04) at the bases
where the emphysema predominates.7 However, in both
studies the numbers recruited were low. Re-analysis of the
original study using the most sensitive methods also reduced
the p value to levels of conventional significance. Further-
more, combining data from both studies providedmore robust
data of efficacy8 indicating the template for any future trials.
However, acquisition of CT data adequate for this complex
analysis is difficult over the multiple sites necessary for such
a trial. It therefore remains critical that such studies are
limited to centres of excellence where sufficient patients are
recruited to ensure the best QC and consistent SOPs.
In summary, the recent revival of research in A1ATD has
improved knowledge of the pathophysiology of COPD, espe-
cially in this genetic disease. The tools have been developed
to conduct small scale yet accurate clinical trials and new
paradigms of treatment are evolving. International collabo-
rationand theconsolidationofexpert centres is crucial for the
future understanding and management of this condition.
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